Homing in on the hepatic scar: recent advances in cell-specific targeting of liver fibrosis

Research output: Contribution to journalLiterature reviewpeer-review

Abstract

Despite the high prevalence of liver disease globally, there are currently no approved anti-fibrotic therapies to treat patients with liver fibrosis. A major goal in anti-fibrotic therapy is the development of drug delivery systems that allow direct targeting of the major pro-scarring cell populations within the liver (hepatic myofibroblasts) whilst not perturbing the homeostatic functions of other mesenchymal cell types present within both the liver and other organ systems. In this review we will outline some of the recent advances in our understanding of myofibroblast biology, discussing both the origin of myofibroblasts and possible myofibroblast fates during hepatic fibrosis progression and resolution. We will then discuss the various strategies currently being employed to increase the precision with which we deliver potential anti-fibrotic therapies to patients with liver fibrosis.

Original languageEnglish
Journal F1000Research
Volume5
DOIs
Publication statusPublished - 19 Jul 2016

Fingerprint Dive into the research topics of 'Homing in on the hepatic scar: recent advances in cell-specific targeting of liver fibrosis'. Together they form a unique fingerprint.

Cite this